Navigation Links
Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
Date:12/5/2007

T I and II preliminary results is ongoing and full data from the IMPACT trials is expected to be presented at an upcoming medical meeting and published in a peer-reviewed journal.

OvaRex MAb-B43.13 (oregovomab) is one of five investigational immunotherapeutic monoclonal antibodies which Unither Pharmaceuticals licensed in April 2002 from AltaRex Medical Corp., a wholly-owned subsidiary of ViRexx Medical Corp. Based on the preliminary results from the IMPACT trials, Unither Pharmaceuticals intends to terminate the license agreement and intends to cease further development of the entire platform of antibodies. United Therapeutics is currently determining the amount of exit costs associated with termination of this program. While a precise estimate of write-down charges is not yet known, United Therapeutics has approximately $7 million in assets related to this program that are subject to write-down during the fourth quarter of 2007.

"Given what appeared to be the promising clinical activity observed in a subset of patients from an earlier phase II trial, we are very surprised by these findings. The IMPACT trials, which were well designed and rigorously conducted, indicate that the approach of triggering tumor-specific immunity using a murine monoclonal antibody has its challenges," said Christopher Nicodemus, MD, Unither Pharmaceuticals' Senior Vice President Clinical Research & Development.

"We are all disappointed that OvaRex did not make it to the finish line as a new therapeutic for ovarian cancer, and we owe a huge debt of gratitude to the women and physicians who participated in the studies," said Peter Gonze, Unither Pharmaceuticals' Chief Operating Officer.

About Ovarian Cancer

Ovarian cancer is the fifth leading cause of cancer deaths among women in the United States. The American Cancer Society estimates that in the United States this year, there will be over 20,000 new cases of ovarian cancer diagnosed and over 15,000 wome
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013  An international roster of experts on malignant ... Santa Monica, Calif. , to discuss ... MPM, a rare form of cancer that results from ... lining of the chest. Hosted by UCLA ... 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant ...
(Date:5/24/2013)... 24, 2013  Sinovac Biotech Ltd. (NASDAQ: ... products in China , announced ... of Sinovac, obtained the Certificate of Good Manufacturing ... China State and Food Administration (CFDA) for its ... and its Changping filing and packaging facility. The ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 ... un destacado desarrollador y fabricante de herramientas de ... diagnosis y tratamiento de la enfermedad vascular periférica ... ensayo ADVISE ( Ad enosine V asodilator ... valuation) II durante la sesión de ensayo clínico ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... QUAD Cinema , one of New York City,s leading art ... documentary, 3 BILLION AND COUNTING (102 ... Sure to spark outrage, Dr. Rutledge, a California physician ... ban on the pesticide DDT in 1972, a ban inspired ...
... The following is a statement issued today ... and CEO Steven C. Anderson, IOM, CAE, and National ... CEO Douglas Hoey, RPh, regarding the proposed rule by ... would withdraw existing provisions of the Medicaid pharmacy reimbursement ...
Cached Medicine Technology:3 BILLION AND COUNTING Opens in New York at The QUAD Cinema 23 BILLION AND COUNTING Opens in New York at The QUAD Cinema 3NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of 'AMP' Rule Currently Blocked by Injunction 2NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of 'AMP' Rule Currently Blocked by Injunction 3
(Date:5/24/2013)... Started in 1982, AMTC’s SHINE event is a biannual ... anniversary. SHINE is a ministry run by three generations of ... daughter, Carey Lewis Arban. , This summer’s SHINE will be ... including the New York Film Academy, The New York Conservatory ... Hollywood and Christian casting directors. They seek top talent ...
(Date:5/24/2013)... Area homeowners dreaming about owning a hot tub ... choose from at factory-direct pricing during the Jacuzzi Hot ... place at Emerald Pool and Patio in Bend, ... industry's leading hot tub brand, scheduled the event as part ... will feature popular hot tub models at up to 50% ...
(Date:5/24/2013)... 24, 2013 Mr. Brian Su, CEO ... Annual EB-5 Investment Summit: Dealmakers Conference in Long Beach, ... focus on exploring alternative finance through EB-5 immigrant investors ... and economic information, and updates to project developers, regional ... industry. , "Our goal is to assist EB-5 ...
(Date:5/24/2013)... BestSatelliteProviders.com the online satellite TV and ... compare the features and services offered by leading ... the rankings of the best rural Internet ... on their website. , BestSatelliteProviders.com – ... Matthews, the spokesperson for BestSatelliteProviders.com, “When consumers were ...
(Date:5/24/2013)... May 24 (HealthDay News) -- Low-income, minority parents ... activity and are more open to vaccinating their ... a small new study contends. Conversely, white, ... vaccination for their daughters, according to researchers from ... 33,000 Americans will get an HPV-related cancer each ...
Breaking Medicine News(10 mins):Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2Health News:Best Rural Internet Service Provider in 2013 by BestSatelliteProviders.com 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2
... study it is observed that the background of the ... at the University of Glasgow have surveyed 4,139 melanoma ... 1999.// They found the outcomes to be similar, whether ... work, or general surgery. This is in contrast to ...
... Albert Einstein College of Medicine, they have observed that ... predict who will develop a form of dementia later ... Medicine finds the presence of an abnormal gait in ... dementia. The form of dementia is non-Alzheimer's dementia. ...
... a new study it is observed that statins reduce the ... statins lowers cholesterol// levels and so lowers the risk of ... in middle-aged people, but the benefits for the elderly have ... of Glasgow have assessed the benefit of treatment with the ...
... have observed that doctors should use lower thresholds when ... in ethnic minorities.// Researchers at St George's Hospital, Georgia ... and women of various ethnic origins, looking at their ... people of African origin have the lowest risk of ...
... is observed that susceptibility to lead is still a ... in blood over the past two decades. Previous ... factor and potential// cause for cancer, kidney disease, cardiovascular ... a small number of studies to investigate the connection ...
... According to researchers in a study working with animals ... and learning. Although the research is early, they say ... memory and learning disorders. Researchers say previous research into ... genes and didn't provide a comprehensive understanding of how ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: